Tibet AIM Pharm. Inc. (SHE:002826)
China · Delayed Price · Currency is CNY 17.59
-0.07 (-0.40%)
Sep 30, 2026, 3:04 PM CST
Tibet AIM Pharm. Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 685.17 | 636.17 | 649.72 | 666.8 | 856.53 | 724.36 |
Other Revenue | -0.72 | 0.11 | 2.16 | 0.23 | 0.21 | 1.1 |
| 684.45 | 636.27 | 651.88 | 667.04 | 856.73 | 725.46 | |
Revenue Growth | 11.96% | -2.40% | -2.27% | -22.14% | 18.09% | 20.38% |
Cost of Revenue | 118.94 | 113.82 | 205.54 | 325.59 | 480.7 | 464.96 |
Gross Profit | 565.51 | 522.45 | 446.34 | 341.45 | 376.03 | 260.5 |
Selling, General & Admin | 458.1 | 433.58 | 390.65 | 298.35 | 317.92 | 218.48 |
Research & Development | 14.22 | 14.67 | 15.48 | 13.71 | 13.35 | 11.39 |
Other Operating Expenses | 26.29 | 10.83 | 12.27 | 11.5 | -8.2 | -9.81 |
Operating Expenses | 497.51 | 457.84 | 419.08 | 316.54 | 329.71 | 218.93 |
Operating Income | 68 | 64.62 | 27.26 | 24.91 | 46.32 | 41.58 |
Interest Expense | -0.59 | -1 | -0.45 | -1.18 | -0.81 | -0.84 |
Interest & Investment Income | 4.16 | 3.94 | 5.2 | 5.06 | 3.93 | 2.92 |
Currency Exchange Gain (Loss) | -0 | -0 | 0 | 0 | 0 | -0 |
Other Non Operating Income (Expenses) | 2.79 | 0.79 | -0.3 | 1.06 | 3.23 | 2.8 |
EBT Excluding Unusual Items | 74.36 | 68.35 | 31.71 | 29.85 | 52.68 | 46.46 |
Impairment of Goodwill | - | - | - | -19.8 | - | - |
Gain (Loss) on Sale of Assets | -0.09 | -0.23 | -0.04 | 0.03 | - | 0.03 |
Asset Writedown | -2.77 | -2.75 | -0.2 | -0.13 | -0.08 | -0.08 |
Other Unusual Items | 76.02 | 48.31 | 28.91 | 13.65 | 4.1 | 3.6 |
Pretax Income | 147.52 | 113.67 | 60.38 | 23.6 | 56.7 | 50.01 |
Income Tax Expense | 25.46 | 20.55 | 12.92 | 7.87 | 10.59 | 6.54 |
Earnings From Continuing Operations | 122.06 | 93.12 | 47.46 | 15.73 | 46.12 | 43.47 |
Minority Interest in Earnings | -0.36 | -0.54 | -1.53 | -0.34 | -1.98 | -1 |
Net Income | 121.7 | 92.58 | 45.93 | 15.39 | 44.14 | 42.48 |
Net Income to Common | 121.7 | 92.58 | 45.93 | 15.39 | 44.14 | 42.48 |
Net Income Growth | 177.61% | 101.57% | 198.50% | -65.14% | 3.91% | 3.37% |
Shares Outstanding (Basic) | 184 | 185 | 184 | 192 | 192 | 193 |
Shares Outstanding (Diluted) | 184 | 185 | 184 | 192 | 192 | 193 |
Shares Change | 0.36% | 0.79% | -4.48% | 0.23% | -0.61% | 3.37% |
EPS (Basic) | 0.66 | 0.50 | 0.25 | 0.08 | 0.23 | 0.22 |
EPS (Diluted) | 0.66 | 0.50 | 0.25 | 0.08 | 0.23 | 0.22 |
EPS Growth | 176.60% | 100.00% | 212.50% | -65.22% | 4.54% | 0% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 227.75 | 115.22 | 99.33 | 163.7 | 65.26 | 84.33 |
Free Cash Flow Per Share | 1.24 | 0.62 | 0.54 | 0.85 | 0.34 | 0.44 |
Dividend Per Share | 0.150 | 0.150 | 0.100 | 0.030 | 0.100 | 0.100 |
Dividend Growth | 50.00% | 50.00% | 233.33% | -70.00% | 0% | 25.00% |
Gross Margin | 82.62% | 82.11% | 68.47% | 51.19% | 43.89% | 35.91% |
Operating Margin | 9.93% | 10.15% | 4.18% | 3.73% | 5.41% | 5.73% |
Profit Margin | 17.78% | 14.55% | 7.05% | 2.31% | 5.15% | 5.85% |
Free Cash Flow Margin | 33.27% | 18.11% | 15.24% | 24.54% | 7.62% | 11.62% |
EBITDA | 85.31 | 83.62 | 48.96 | 49.05 | 69.02 | 65.24 |
EBITDA Margin | 12.46% | 13.14% | 7.51% | 7.35% | 8.06% | 8.99% |
D&A For EBITDA | 17.31 | 19 | 21.69 | 24.14 | 22.7 | 23.66 |
EBIT | 68 | 64.62 | 27.26 | 24.91 | 46.32 | 41.58 |
EBIT Margin | 9.93% | 10.15% | 4.18% | 3.73% | 5.41% | 5.73% |
Effective Tax Rate | 17.26% | 18.07% | 21.39% | 33.37% | 18.67% | 13.08% |
Revenue as Reported | 684.45 | 636.27 | 651.88 | 667.04 | 856.73 | 725.46 |